StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.44+0.03 (+2.13%)

Close on Nov 17, 2026Market cap $120.11MP/E –Yield –

Pyxis Oncology cash

Cash and short-term investments held at the end of each period.

Pyxis Oncology's cash was $33.00M at Jun 30, 2026. For fiscal 2025 it was $66.90M, down 47.3% from the year before. The highest annual figure on record is $274.74M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.90M-47.3%
FY2024Dec 31, 2024$126.90M+6.4%
FY2023Dec 31, 2023$119.30M-33.5%
FY2022Dec 31, 2022$179.29M-34.7%
FY2021Dec 31, 2021$274.74M+3300.2%
FY2020Dec 31, 2020$8.08M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.00M-62.9%
Q1 FY2026Mar 31, 2026$41.00M-61.1%
Q4 FY2025Dec 31, 2025$66.90M-47.3%
Q3 FY2025Sep 30, 2025$76.30M-47.3%
Q2 FY2025Jun 30, 2025$88.90M-42.9%
Q1 FY2025Mar 31, 2025$105.40M-32.9%
Q4 FY2024Dec 31, 2024$126.90M+6.4%
Q3 FY2024Sep 30, 2024$144.80M+8.9%
Q2 FY2024Jun 30, 2024$155.70M+9.1%
Q1 FY2024Mar 31, 2024$157.00M+5.2%
Q4 FY2023Dec 31, 2023$119.30M-33.5%
Q3 FY2023Sep 30, 2023$133.00M-33.0%
Q2 FY2023Jun 30, 2023$142.70M-36.1%
Q1 FY2023Mar 31, 2023$149.30M-39.6%
Q4 FY2022Dec 31, 2022$179.29M-34.7%
Q3 FY2022Sep 30, 2022$198.54M+48.7%
Q2 FY2022Jun 30, 2022$223.36M+56.8%
Q1 FY2022Mar 31, 2022$247.09M+75.7%
Q4 FY2021Dec 31, 2021$274.74M+3300.2%
Q3 FY2021Sep 30, 2021$133.48M+1086.9%
Q2 FY2021Jun 30, 2021$142.47M–
Q1 FY2021Mar 31, 2021$140.66M–
Q4 FY2020Dec 31, 2020$8.08M–
Q3 FY2020Sep 30, 2020$11.25M–

More Pyxis Oncology figures

See a number that looks wrong?